BR9910568A - Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos - Google Patents

Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos

Info

Publication number
BR9910568A
BR9910568A BR9910568-3A BR9910568A BR9910568A BR 9910568 A BR9910568 A BR 9910568A BR 9910568 A BR9910568 A BR 9910568A BR 9910568 A BR9910568 A BR 9910568A
Authority
BR
Brazil
Prior art keywords
agonist
csf receptor
receptor
selection process
receptor antibodies
Prior art date
Application number
BR9910568-3A
Other languages
English (en)
Inventor
Baofu Ni
Bill N C Sun
Cecily R Y Sun
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of BR9910568A publication Critical patent/BR9910568A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Patente de Invenção: <B>"ANTICORPOS AGONISTAS DE RECEPTOR DE G-CSF E PROCESSO DE SELEçãO PARA OS MESMOS"<D>. A invenção refere-se a moléculas agonistas que se ligam especificante a ou interagem com o receptor de G-CSF humano e dimerizam o receptor ou ativam a fosforilação de quinases associadas com o receptor para estimular a proliferação e a diferenciação celular. Tais moléculas agonistas incluem anticorpos monoclonais, ou fragmentos, homólogos ou análogos destas ou peptídeos ou compostos orgânicos. São descritos dois exemplos de anticorpos agonistas monoclonais de camundongo: mAb 163-93 e mAb174-74-11.
BR9910568-3A 1998-04-30 1999-04-30 Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos BR9910568A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8357598P 1998-04-30 1998-04-30
PCT/US1999/009466 WO1999055735A1 (en) 1998-04-30 1999-04-30 G-csf receptor agonist antibodies and screening method therefor

Publications (1)

Publication Number Publication Date
BR9910568A true BR9910568A (pt) 2001-09-11

Family

ID=22179233

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910568-3A BR9910568A (pt) 1998-04-30 1999-04-30 Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos

Country Status (12)

Country Link
EP (1) EP1073683B1 (pt)
JP (1) JP3979008B2 (pt)
KR (1) KR100479790B1 (pt)
CN (2) CN1326880C (pt)
AT (1) ATE314396T1 (pt)
AU (2) AU764653B2 (pt)
BR (1) BR9910568A (pt)
CA (1) CA2326755A1 (pt)
DE (1) DE69929183T2 (pt)
ES (1) ES2253887T3 (pt)
NZ (1) NZ507782A (pt)
WO (1) WO1999055735A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061389A2 (en) * 2001-02-01 2002-08-08 Tanox, Inc. Methods to generate and identify monoclonal antibodies to a large number of human antigens
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
CN101720355A (zh) * 2007-06-07 2010-06-02 福田惠一 使用g-csf分化诱导成心肌细胞的方法
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
BR112013022052A2 (pt) 2011-03-01 2016-11-22 Novo Nordisk As ligantes antagonísticos de dr3
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
CN107810420B (zh) * 2015-06-25 2020-08-14 豪夫迈·罗氏有限公司 用于测定抗体或配体结合和功能的基于细胞的测定
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
CA3229748A1 (en) * 2021-08-26 2023-03-02 Akifumi Kato Bispecific antibody that binds to cd116 and cd131
CN114292843B (zh) * 2021-12-03 2023-07-21 中国科学院精密测量科学与技术创新研究院 一种基因兴奋剂的CRISPR/Cas12a检测体系及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JP3417558B2 (ja) * 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
AUPM375094A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules and methods for assaying cytokine function
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
WO1997012977A1 (en) * 1995-10-05 1997-04-10 G.D. Searle & Co. Novel g-csf receptor agonists

Also Published As

Publication number Publication date
AU2003252863A1 (en) 2003-11-06
CN1298412A (zh) 2001-06-06
DE69929183D1 (de) 2006-02-02
NZ507782A (en) 2003-12-19
AU764653B2 (en) 2003-08-28
JP3979008B2 (ja) 2007-09-19
ES2253887T3 (es) 2006-06-01
JP2002512782A (ja) 2002-05-08
KR20010043112A (ko) 2001-05-25
ATE314396T1 (de) 2006-01-15
EP1073683A1 (en) 2001-02-07
CN1326880C (zh) 2007-07-18
AU3673299A (en) 1999-11-16
DE69929183T2 (de) 2006-08-24
EP1073683B1 (en) 2005-12-28
CN101070344A (zh) 2007-11-14
WO1999055735A1 (en) 1999-11-04
EP1073683A4 (en) 2001-08-22
KR100479790B1 (ko) 2005-03-30
CA2326755A1 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
BR9910568A (pt) Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
AR005397A1 (es) Anticuerpo agonista monoclonal que se liga especificamente al receptor ob, un metodo para mejorar la proliferacion o diferenciacion in vitro de una celula que comprende un receptor ob, el uso de un anticuerpo agonista anti-receptor ob para la preparacion de una dosificacion fisiologicamente aceptable, y metodos para identificar un anticuerpo que se liga o activa al receptor ob que incrementa la proliferacion o diferenciacion de una celula
CY1112101T1 (el) Νευροτροφικοι παραγοντες
BR9713914A (pt) Composto, uso do mesmo, composição farmacêutica, e processo para tratar um paciente sofrendo de um distúrbio que é susceptìvel a tratamento com um agonista da trombopoietina.
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
ATE382053T1 (de) System zur antikörperexpression und- synthese
BR0113921A (pt) ácidos nucléicos e polipeptìdeos receptores
EA200801732A1 (ru) Модуляторы ауроракиназы, способы их получения и их применение
EA200500647A1 (ru) Антитела, связывающие клеточные полипептиды ca 125/0772p, и способы их применения
SG170080A1 (en) Human monoclonal antibodies to o8e
AR045056A1 (es) Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
WO2003038063A3 (en) Human secreted proteins
BRPI0618399A2 (pt) região de ligação de antìgeno isolada que é especìfica para cd38, anticorpo isolado ou um fragmento funcional do mesmo que é especìfico para cd38, anticorpo isolado ou um fragmento funcional do mesmo, imunoglobulina isolada, cadeia pesada variável de uma região de ligação de antìgeno isolada, cadeia leve variável de uma região de ligação de antìgeno isolada, seqüência isolada de ácido nucléico, seqüência de ácido nucléico que codifica uma cadeia pesada variável de uma região de ligação de antìgeno isolada, seqüência de ácido nucléico, vetor, célula isolada, composição farmacêutica, uso da composição farmacêutica, método de indução de mortandade especìfica das células de tumor que expressam cd38, método de detecção da mortandade especìfica das células de tumor que expressam cd38, método de detecção da presença de cd38 em um tecido ou em célula de origem de miniporco, método de detecção de cd38 em um eritrócito que expressa cd38 e composição de diagnóstico
IL159177A0 (en) Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
NO20011759D0 (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
BR9814335A (pt) Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
DE60041452D1 (de) CpG REZEPTOR (CpG-R) UND DARAUF BEZOGENE METHODEN
BR112022007619A2 (pt) Molécula de ligação específica, molécula de fusão de molécula de ligação específica anti-cd3, ácido nucleico, vetor de expressão, célula, célula de ocorrência não natural e/ou purificada e/ou geneticamente modificada, composição farmacêutica, método para tratar um sujeito humano com câncer ou tumor e método para produzir uma molécula de ligação específica
PH12021553197A1 (en) Anti-cd47 antibodies and uses thereof
Benjamin et al. Platelet-derived growth factor stimulates growth factor receptor binding protein-2 association with Shc in vascular smooth muscle cells.
BR0308401A (pt) Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento.
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
WO1996031603A3 (en) Methods and compositions for regulating fadd

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.